Predictive Oncology Free Cash Flow 2010-2025 | POAI

Predictive Oncology free cash flow from 2010 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.

Predictive Oncology Free Cash Flow 2010-2025 | POAI

Predictive Oncology free cash flow from 2010 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Related Stocks
Company NameMarket
Cap
Veeva Systems (VEEV)$47.6B
Hims & Hers Health (HIMS)$12.8B
Doximity (DOCS)$11.4B
Tempus AI (TEM)$11B
IRhythm Technologies (IRTC)$4.2B
Inspire Medical Systems (INSP)$3.8B
Hinge Health (HNGE)$3.6B
Privia Health (PRVA)$2.4B
10x Genomics (TXG)$1.7B
Schrodinger (SDGR)$1.7B
Phreesia (PHR)$1.6B
Clover Health Investments (CLOV)$1.6B
Azenta (AZTA)$1.6B
Enovis (ENOV)$1.6B
Omnicell (OMCL)$1.3B
Evolent Health (EVH)$1.1B
Claritev (CTEV)$686M
Fulgent Genetics (FLGT)$560M
Standard BioTools (LAB)$558M
Veradigm (MDRX)$523M
Butterfly Network (BFLY)$514M
Talkspace (TALK)$422M
TruBridge (TBRG)$349M
Outset Medical (OM)$312M
Health Catalyst (HCAT)$268M
Nyxoah SA (NYXH)$265M
SOPHiA GENETICS SA (SOPH)$241M
CapsoVision (CV)$198M
Zepp Health (ZEPP)$165M
KORU Medical Systems (KRMD)$162M